Related Experiment Videos
First-line therapy for advanced colorectal cancer
Aimery de Gramont1, Christophe Tournigand, Christophe Louvet
1Service de Médecine Interne-Oncologie, Hôpital Saint-Antoine, 184 rue du Faubourg Saint Antoine, 75571 Paris, Cedex 12, France. aimery.de-gramont@sat.aphp.fr
Current Oncology Reports
|April 26, 2005
Summary
First-line therapy for advanced colorectal cancer now involves complex regimens with new drugs like oxaliplatin and targeted therapies. Treatment decisions integrate prognostic factors, surgery, and future therapies, influenced by resource availability.
Area of Science:
- Oncology
- Medical Treatment
Background:
- Traditional fluoropyrimidine-based therapies are evolving for advanced colorectal cancer.
- Newer chemotherapy agents and targeted therapies are becoming standard.
- Treatment selection is increasingly complex.
Purpose of the Study:
- To outline the evolving landscape of first-line therapy for advanced colorectal cancer.
- To highlight the integration of novel agents and treatment strategies.
- To acknowledge the impact of resource limitations on treatment decisions.
Main Methods:
- Review of current treatment paradigms for advanced colorectal cancer.
- Analysis of novel chemotherapy drugs (oxaliplatin, irinotecan).
- Evaluation of targeted therapies inhibiting angiogenesis and EGFR.
Main Results:
- First-line therapy has shifted to more complex and active regimens.
- Treatment choice incorporates prognostic factors, salvage surgery, and second-line planning.
- Financial resources are a growing consideration in disease management.
Conclusions:
- Advanced colorectal cancer treatment requires a multifaceted, individualized strategy.
- The integration of novel agents necessitates a re-evaluation of therapeutic approaches.
- Economic factors play a significant role in the practical application of advanced cancer care.